Meet The Team Who’s
Pioneering Therapies For
Life-Threatening Inflammatory
Diseases With High Unmet
Need
The CalciMedica team is comprised of scientists, physicians, drug development experts and entrepreneurs dedicated to the development of CRAC channel inhibitors for acute and chronic inflammatory conditions.
A. Rachel Leheny, Ph.D.
Dr. Leheny has over 30 years of experience in the life sciences industry as a scientist, a research analyst at several investment banks and as a venture capital investor. Dr. Leheny is a Founding Managing Director for Valence Advantage Life Sciences, a venture firm based in New York. Prior to Valence, she co-founded Caxton Advantage Venture Partners, from which Valence Life Sciences emerged. Before that, she was a Senior Vice President and Head of the biotechnology research team at Lehman Brothers.
She also led the biotechnology research team at UBS Warburg. She started her biotechnology research career at Hambrecht and Quist. Dr. Leheny obtained an A.B. in Chemistry with honors from Harvard College, and a Ph.D. in chemistry from Columbia University. She did post-doctoral work at the University of California, Berkeley, where she was an NIH fellow and a lecturer.
Officer
Michael J. Dunn, MBA
Officer
Mr. Dunn has 35 years of experience in the pharmaceutical and biotech industries. Before joining CalciMedica, Mr. Dunn was Senior Vice President, Corporate Development at Biocept, Inc., a company focused on the analysis of circulating tumor cells (CTCs) to better target therapy for cancer patients. Prior to that, he served as Vice President and Chief Business Officer of Monogram Biosciences, a biotech clinical laboratory specializing in infectious disease and cancer testing, which was acquired by LabCorp in 2009. Mr. Dunn served as Vice President and Chief Business Officer of ACLARA Biosciences, a company specializing in microfluidic chips and oncology testing, through its merger with ViroLogic, Inc., which became Monogram Biosciences. Before that he was Vice President and Chief Business Officer at ActivX Biosciences, a biopharmaceutical company that utilized proteomics for small molecule drug discovery, which was acquired by Kyorin Pharmaceuticals of Japan.
Additionally, Mr. Dunn served as Vice President of Business Development at Aurora Biosciences, a company that developed and commercialized proprietary drug discovery systems and services through its acquisition by Vertex Pharmaceuticals, and in various project management and business development roles at Salk Institute Biotechnology Industrial Associates, Inc. (SIBIA) and its successor SIBIA Neurosciences, culminating as Vice President of Business Development. SIBIA was acquired by Merck. Mr. Dunn holds a B.A. in Biology from the University of Chicago and an MBA with an emphasis in Finance from the University of San Diego.
Chairman of the Board
Eric W. Roberts
Chairman of the Board
Mr. Roberts has 30 years of experience in the finance, investment and life sciences industry and has completed hundreds of financings and merger transactions. Mr. Roberts is currently Vice Chairman of the Board of CalciMedica Inc. He has served on the boards of a number of public and private life science companies. In 2012, Mr. Roberts co-founded the investment firm, Valence Life Sciences. Prior to Valence Life Sciences, Mr. Roberts managed the Caxton Advantage Life Sciences Fund which he co-founded in 2005. Prior to Caxton Advantage, he was Managing Director and Co-Head of the Global Healthcare Investment Banking Group at Lehman Brothers.
Mr. Roberts was also a Managing Director, Partner and founder of the Life Sciences Department at Dillon, Read & Co. Inc. which was ultimately merged into UBS. At UBS, Mr. Roberts ran the Life Sciences investment banking team. Earlier in his career, Mr. Roberts worked at the Citicorp Venture Capital (CVC) group. Mr. Roberts received a B.S. in Economics from the Wharton School of the University of Pennsylvania. He is also a Director of the Cary Institute for Ecosystem Studies, the Atlantic Salmon Federation and is a past Director of the American Museum of Fly Fishing.
John M. Dunn
Mr. Dunn has over 25 years of experience practicing corporate law in the life science industry. Mr. Dunn serves on the Boards of Acer Therapeutics, a publicly traded pharmaceutical company, Sharp Healthcare, a San Diego not-for-profit healthcare system, and Biocom and Connect, non-profit organizations supporting the life science and technology industries in the San Diego area. Over the last 15 years Mr. Dunn has also served as a senior advisor to TVM Capital, a life science venture capital firm. Mr. Dunn recently served as General Counsel and Secretary of Vital Therapies, Inc., a public biotech company, until its merger with Immunic, Inc. Previously, he spent 10 years at Biogen Idec where he was an Executive Vice President and the head of their corporate venture group, which made and managed strategic investments in emerging biotech companies.
Prior to the merger of IDEC Pharmaceuticals and Biogen, Mr. Dunn served on the senior management team as Senior Vice President and General Counsel of IDEC where he led its legal and compliance departments. Mr. Dunn was a partner at the law firm of Pillsbury Winthrop Shaw Pitman. He earned a B.S. in finance and a J.D. from the University of Wyoming.
Sudarshan Hebbar, M.D.
Dr. Hebbar has over 15 years of clinical development and product development experience in both the pharmaceutical and diagnostics industries. Before joining CalciMedica, Dr. Hebbar was a consultant for Mallinckrodt Pharmaceuticals, where he served as the clinical development lead for a global multicenter Phase IV trial. Prior to that, he was the Vice President of Nephrology at Thrasos Innovation where he helped implement a global multicenter Phase II trial of a novel therapeutic compound for acute kidney injury. Before working at Thrasos, Dr. Hebbar served as Medical Vice President and a member of the U.S. Board of Directors at Oncimmune, a company that pioneered the development of autoantibody assay technologies for the early detection of lung cancer. Before joining Oncimmune, Dr. Hebbar served as a Medical Director at Reata Pharmaceuticals, where he was a medical monitor for both a Phase III global multicenter trial and multiple Phase I trials, and the clinical development lead for multiple Phase II trials. Dr. Hebbar began his industry career at Abbott, where he initially served as a Senior Medical Director in the Quality and Regulatory division before transferring to the Diagnostics division, where he supervised a team that provided medical input into product development, supported commercial launches of diagnostic products and led the clinical development of novel biomarkers.
Prior to joining Abbott, Dr. Hebbar was a Medical Director at Dialysis Clinics Incorporated and a partner at Kidney Associates of Kansas City where for 12 years he practiced nephrology, hypertension, transplant medicine and critical care medicine. Dr. Hebbar received a B.A. in Natural Sciences from The Johns Hopkins University and a M.D. from Tulane University School of Medicine. He completed a residency in Internal Medicine and a fellowship in Critical Care Medicine, both at Hennepin County Medical Center, a fellowship in Nephrology at the University of Chicago and a fellowship in Clinical Medical Ethics at The Maclean Center for Clinical Medical Ethics at the University of Chicago
Kenneth A. Stauderman, Ph.D.
Dr. Stauderman brings more than 30 years of research and management experience in pharmaceuticals and biotechnology, and has an extensive research background in mechanisms controlling intracellular calcium. Prior to co-founding CalciMedica with Dr. Gonul Velicelebi and joining the company in April 2007, Dr. Stauderman was Executive Director of Biology and Lead Discovery at TorreyPines Therapeutics, since its inception as Neurogenetics, Inc. While at TorreyPines, he directed two successful drug discovery programs and one target discovery initiative that led to the discovery of STIM1 as a key regulator of calcium release-activated Ca2+ channels.
Prior to TorreyPines Therapeutics, Dr. Stauderman was Director of Molecular and Cell Biology at SIBIA Neurosciences, Inc. (which later became Merck Research Laboratories, San Diego) from 1994-2000 and Senior Scientist at Marion Merrell Dow Pharmaceuticals (now Sanofi-Aventis; 1986-1994). Dr. Stauderman has authored/co-authored over 50 scientific publications and is an inventor on several patents. Dr. Stauderman received a B.A. in Psychology from the University of Virginia and a Ph.D. in Pharmacology from the University of Texas Health Science Center in San Antonio, Texas.
Stephen Bardin, MBA
Mr. Bardin has over 10 years of experience in the life science industry in financial strategy, operations, and corporate development. Before joining CalciMedica, Mr. Bardin served as Chief Financial Officer of atai Life Sciences (Nasdaq: ATAI) where he played a key role in the company’s investor relations, business development, capital allocation, and financial operations activities. Prior to that, he spent nearly three years at BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company with a broad pipeline of development programs, where he oversaw a broad range of finance activities and helped raise over $2B through a variety of financing transactions.
Prior to that, Mr. Bardin held positions focused on finance, operations, and corporate development at Myovant Sciences, Inc., a subsidiary of Roivant (Nasdaq: ROIV) at the time. He began his career advising life sciences companies at the Boston Consulting Group. Mr. Bardin holds an M.B.A. from the Stanford Graduate School of Business and graduated summa cum laude from Duke University with a B.S.E. in Biomedical Engineering.
Raven D. Jaeger
Raven Jaeger, M.S. has over 20 years of experience in the pharmaceutical and biotech industries as a Regulatory Affairs professional. Mrs. Jaeger brings with her experience with investigational and commercialized drugs and biologics for the treatment of serious and unmet medical needs, with much of her experience working towards the treatment of rare diseases. During her career, Mrs. Jaeger worked in multiple therapeutic areas, including rare genetic disorders, neurology, oncology, immunology, cardiology, and metabolic diseases.
Prior to joining CalciMedica, Mrs. Jaeger was the Chief Regulatory Officer at Diffusion Pharmaceuticals, where she supported the product development program and various business activities.
Previously, Mrs. Jaeger served as a Sr. Vice President of Regulatory Affairs for two subsidiary companies of BridgeBio Pharma and led her team to the first approved NDA across all subsidiaries at the organization. She also obtained approvals for rare diseases at Leadiant Biosciences, Inc. as the head of the Regulatory Affairs Team and during her tenure at ICON Development Solutions. Mrs. Jaeger also worked at Nabi Biopharmaceuticals in regulatory support and management roles after a brief time working at NIH post completion of her undergraduate studies.
Mrs. Jaeger obtained a B.S from The John’s Hopkins University in natural sciences with an emphasis in Biology and Biophysics, and subsequently obtained a M.S. in Biotechnology from the University of Maryland.
Andrew (Andy) Cunningham, M.D., MRCPI
Dr. Cunningham has over 10 years of clinical development experience in the pharmaceutical industry. Prior to this position, Dr. Cunningham served as a consultant for CalciMedica since December 2022. He has valuable leadership and clinical development experience, having served as Head of the Neurodegenerative Franchise at Taysha Gene Therapies and Associate Vice President of Clinical Development at Reata Pharmaceuticals. In his prior Medical Director positions at Takeda Pharmaceutical Company, Sanofi Genzyme and Reata Pharmaceuticals, Dr. Cunningham helped advance drug candidates through all stages of clinical development as well as participated in the filing of New Drug Applications.
Prior to joining the pharmaceutical industry, Dr. Cunningham was Chief Fellow at the Vanderbilt University Medical Center Clinical Pharmacology department. Dr. Cunningham received a B.Sc. in Physiology; MB BCh BAO and MBA from University College Dublin. He completed his internal medicine training and accreditation at Beaumont Hospital, Dublin (MRCPI) and Pharmaceutical Medicine training at Trinity College, Dublin (DipPharmMed).
Sean P. Lawler
Mr. Lawler has 30 years of experience in finance and accounting operations and 15 years in the life science industry. Previously, Mr. Lawler was Controller for Immunic Therapeutics, a company focused on chronic inflammatory and autoimmune diseases, from December 2018 to August 2020, where he contributed significantly to the integration of its merger with Vital Therapies, and Director of Accounting Operations for Vital Therapies, a company focused on cell-based therapies for acute forms of liver failure from April 2015 to November 2018. Prior to Vital Therapies, Mr. Lawler held various roles in accounting and finance with Volcano Corporation, a company that developed and commercialized intravascular imaging for coronary and peripheral applications, and NuVasive, a company that develops medical devices and procedures for minimally invasive spine surgery.
Prior to NuVasive, Mr. Lawler held various accounting and finance roles in the retail, distribution and telecom industries. He received his Bachelor of Science in Finance and Minor in Economics from San Diego State University and is a Certified Public Accountant in the state of California.
Robert N. Wilson
Mr. Wilson brings a wealth of expertise in the pharmaceutical, biotech and medical device industries, having held leadership roles on boards and been Chairman of various companies and organizations including Johnson & Johnson, the Pharmaceutical Research and Manufacturers of America (PhRMA), Synta Pharmaceuticals Corporation and Mevion Systems, among others. In addition, Mr. Wilson previously served as a member of the board of directors of Charles Schwab Corporation, Hess Corporation and as Chairman of Caxton Health Holdings, leading efforts in pharmaceutical and health technology investments.
Prior to that, Mr. Wilson served in several roles at Johnson & Johnson, notably as Vice Chairman of the Board of Directors for 15 years and on the executive committee for 20 years. During his nearly 40-year tenure at Johnson & Johnson, he played a key role in the expansion of the pharmaceutical, device and diagnostic programs while establishing the company as a leader in the search for new solutions for patients. He holds a Bachelor’s degree from Georgetown College in Kentucky.
A. Rachel Leheny, Ph.D.
Dr. Leheny has over 30 years of experience in the life sciences industry as a scientist, a research analyst at several investment banks and as a venture capital investor. Dr. Leheny is a Founding Managing Director for Valence Advantage Life Sciences, a venture firm based in New York. Prior to Valence, she co-founded Caxton Advantage Venture Partners, from which Valence Life Sciences emerged. Before that, she was a Senior Vice President and Head of the biotechnology research team at Lehman Brothers.
She also led the biotechnology research team at UBS Warburg. She started her biotechnology research career at Hambrecht and Quist. Dr. Leheny obtained an A.B. in Chemistry with honors from Harvard College, and a Ph.D. in chemistry from Columbia University. She did post-doctoral work at the University of California, Berkeley, where she was an NIH fellow and a lecturer.
Chairman of the Board
Eric W. Roberts
Chairman of the Board
Mr. Roberts has 30 years of experience in the finance, investment and life sciences industry and has completed hundreds of financings and merger transactions. Mr. Roberts is currently Vice Chairman of the Board of CalciMedica Inc. He has served on the boards of a number of public and private life science companies. In 2012, Mr. Roberts co-founded the investment firm, Valence Life Sciences. Prior to Valence Life Sciences, Mr. Roberts managed the Caxton Advantage Life Sciences Fund which he co-founded in 2005. Prior to Caxton Advantage, he was Managing Director and Co-Head of the Global Healthcare Investment Banking Group at Lehman Brothers.
Mr. Roberts was also a Managing Director, Partner and founder of the Life Sciences Department at Dillon, Read & Co. Inc. which was ultimately merged into UBS. At UBS, Mr. Roberts ran the Life Sciences investment banking team. Earlier in his career, Mr. Roberts worked at the Citicorp Venture Capital (CVC) group. Mr. Roberts received a B.S. in Economics from the Wharton School of the University of Pennsylvania. He is also a Director of the Cary Institute for Ecosystem Studies, the Atlantic Salmon Federation and is a past Director of the American Museum of Fly Fishing.
and Board Member to a Portfolio of
Biopharmaceutical Companies
Allan L. Shaw
and Board Member to a Portfolio of
Biopharmaceutical Companies
Mr. Shaw brings over 20 years of leadership experience managing public companies from a financial, operational, and strategic perspective. He has served on five public boards including chairing two audit committees and two compensation committees, and is currently involved with a portfolio of healthcare activities, including serving as Portage Biotech’s Chief Financial Officer. He is also a five-time public company Chief Financial Officer and an experienced deal executive, who has structured, directed, negotiated and closed over $4 billion in public and private financings for several companies. Previously, Mr. Shaw was the Chief Financial Officer and Treasurer of Syndax Pharmaceuticals, Inc. and was Managing Director of Alvarez & Marsal LLC, a global professional services firm, leading their biopharmaceutical consulting practice.
Mr. Shaw’s previous experience includes serving as the Chief Financial Officer of Serono S.A., NewLead Holdings Ltd. and Viatel, Inc. Mr. Shaw is the founder and Senior Managing Director of Shaw Strategic Capital LLC, an international financial advisory firm focused on providing strategic financial counsel on a wide variety of issues such as general corporate finance, mergers and acquisitions, capital structuring, licensing and capital markets. Mr. Shaw received a B.S. from the State University of New York at Oswego and is a certified public accountant in the State of New York as well as a chartered global management accountant.
Ventures
Fred Middleton, MBA
Ventures
Mr. Middleton has over thirty years of experience in the biotechnology and biomedical industries in both corporate operating management and as an institutional venture capital investor. At Sanderling, he has worked as an investor, management team member and director in over 20 new biomedical ventures built in Sanderling’s venture investment portfolios since 1988. Recently, he has played an active role as Chairman, CEO or Director of a number of current Sanderling portfolio companies, including as Chairman of Pacira Pharmaceuticals, Stereotaxis, Viacyte and Altor Biosciences. He also served as an early stage investor and director of Regeneron Pharmaceuticals, CardioNet, Endocyte, LineaGen, Inc. and Actimis. In 1978, Mr. Middleton joined Bob Swanson and Herb Boyer, the founders of biotechnology pioneer Genentech, Inc., as the third member of the original management team, where he served in various capacities, including Vice President of Finance, Administration, Corporate Development, Chief Financial Officer, and as President of Genentech Development Corporation.
While at Genentech, Mr. Middleton successfully completed over $200 million in corporate partnering and institutional funding transactions, which included managing the Company’s (and the biotech industry’s first) successful IPO in 1980. In 1984, Mr. Middleton founded Morgan Stanley Ventures, an affiliate of Morgan Stanley, serving as Managing General Partner of an institutional fund making technology investments. Mr. Middleton joined Sanderling in 1987 as a General Partner and Managing Director to invest in and build early stage biomedical companies. Mr. Middleton earned his B.S. in chemistry from the Massachusetts Institute of Technology in 1971 and received an M.B.A with distinction from Harvard Business School in 1973. In 2007, he was elected to serve as a member of the M.I.T. Corporation.
Fred Guerard, PharmD
Dr Fred Guerard has more than 25 years of leadership, strategic and commercial experience as a pharmaceutical executive. He currently serves as Chief Executive Officer of Opthea (NASDAQ: OPT, ASX: OPT). He was previously President and Chief Executive Officer of Graybug Vision, Inc. (NASDAQ: GRAY) where he led the company through a $80 Million Series C round in 2019 and a $100 Million IPO in 2020, followed by a merger with CalciMedica (NASDAQ: CALC) in 2023.
Prior to joining Graybug, Dr Guerard was Worldwide Business Franchise Head of Ophthalmology at Novartis. He led the integration of the global Alcon Pharma and Novartis retina businesses and was responsible for several deals leading to a significant extension of Novartis’ ophthalmology pipeline.
During his 20-year tenure at Novartis, Dr Guerard held additional leadership positions, including Global Franchise Head of Pharmaceuticals at Alcon, Country Head of the United Kingdom and Ireland, Country Head and President of Australia and New Zealand, Head of Marketing and Sales for Emerging Growth Markets Region, Country Head and President of Egypt, and Country Cluster Head of North and West Africa.
Dr Guerard holds a PharmD and a Master of biological and Medical Sciences from the University of Rouen, France, and a Master of Marketing from the international business school HEC (Hautes Etudes Commerciales), Paris.
He served on the Boards of the Association of the British Pharmaceutical Industry (ABPI) and on the Board of Medicines Australia, and currently serves as non-executive director on the Boards of CalciMedica (NASDAQ: CALC), Lenz Therapeutics, Spiral Therapeutics, and Unither Pharmaceuticals.
Alan Glicklich, M.D
Dr Alan Glicklich has more than 20 years of experience in the biotech industry. At Nuvig Therapeutics, a company pursuing multiple inflammatory autoimmune diseases, Dr. Glicklich is currently leading a clinical team planning to initiate multiple Phase 2 trials. Prior to Nuvig, Dr. Glicklich was Chief Medical Officer of Chinook Therapeutics, where he was responsible for the clinical development, clinical operations, medical affairs, biometrics, regulatory, and pharmacovigilance teams. While at Chinook, he designed and operationalized a successful Phase 3 registrational study for atrasentan in IgA nephropathy as well as multiple earlier phase studies across rare chronic kidney disease indications.
Before that, Dr. Glicklich was Chief Medical Officer at Bird Rock Bio, where he focused on monoclonal antibody development for inflammatory and fibrotic diseases. Prior to Bird Rock, he was Vice President of Clinical Development at Arena Pharmaceuticals, where he designed and operationalized two Phase 2 programs in pulmonary arterial hypertension and ulcerative colitis. Dr. Glicklich has also held positions at BMS, Sanofi-Aventis, and Regeneron. Dr. Glicklich holds an M.D. from the University of Wisconsin and an M.B.A. from the Emory University-Goizueta School of Business, as well as a B.A. in Biology from the University of Chicago.
CalciMedica’s current drug development efforts build on nearly two decades of research into the role of CRAC channels in the immune response as well as preclinical and clinical research demonstrating the potential therapeutic benefit of CRAC channel inhibitors in life-threatening inflammatory diseases. CalciMedica was founded in 2007 by Dr. Ken Stauderman and colleagues from TorreyPines Therapeutics, along with a team from Harvard’s CBR Institute for Biomedical Research. Dr. Stauderman is a world leader in CRAC channel biology and pharmacology.
2005
Dr. Ken Stauderman and collaborators, as well as CalciMedica co-founders, discovered the role of STIM1, in conjunction with Orai1, in forming CRAC channels targeted by CalciMedica’s drug compounds.
2007
CalciMedica was founded by scientists from TorreyPines Therapeutics, including Dr. Stauderman, CalciMedica’s Co- founder and Chief Scientific Officer, and a team from Harvard’s CBR Institute for Biomedical Research comprised of Drs. Anjana Rao, Patrick Hogan (both currently at the La Jolla Institute for Immunology) and Stefan Feske (currently at NYU School of Medicine).
2008
At CalciMedica, Dr. Stauderman and a team of skilled scientists developed a series of proprietary assays that, combined with a strong internal medical chemistry effort, led to the identification and optimization of a portfolio of potent and highly selective CRAC channel inhibitors.
2011
CalciMedica advanced the first CRAC channel inhibitor into human clinical studies. This compound demonstrated safety and trends towards efficacy as an orally administered agent in patients with moderate to severe plaque psoriasis.
2012
Different CalciMedica CRAC channel compounds were developed with improved potency and selectivity; CM4620 (the intravenous (IV) formulation of which was named Auxora™, and became CalciMedica’s lead compound) was selected for development
2016
Auxora™ entered into clinical development, proceeding through Phase 1 studies in healthy volunteers and two Phase 2 studies in patients with acute pancreatitis, especially acute pancreatitis with accompanying SIRS and hypoxemia.
2020
Two Phase 2 clinical studies of Auxora were conducted on severe and critical COVID-19 pneumonia patients receiving supplemental oxygen but not mechanical ventilation, demonstrating safety and efficacy.
A dose-escalation study was performed on critical COVID-19 patients on mechanical ventilation.
An investigator-sponsored study in pediatric ALL patients with asparaginase-induced pancreatic toxicity was initiated.
Other proprietary CRAC channel compounds were selected for preclinical development, including ones with properties amenable for oral dosing
2021
CalciMedica initiates
Phase 2b study in AP with SIRS
2023
2023 CalciMedica completes reverse merger and becomes a publicly traded company.
In 2016, CalciMedica advanced its lead compound, Auxora™, into clinical development. Auxora™, a proprietary, intravenous-formulated CRAC channel inhibitor, has demonstrated positive and consistent clinical results and has been well-tolerated in four completed Phase 2 clinical trials. Auxora™ is in development for acute pancreatitis and asparaginase-induced pancreatic toxicity.
CalciMedica, Inc., is focused on further developing Auxora™, to treat life-threatening inflammatory diseases, such as acute pancreatitis (AP), asparaginase-induced pancreatic toxicity (AIPT), acute kidney injury (AKI), and acute respiratory distress syndrome (ARDS), for which there are no currently approved therapies.
